English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, January 11, 2022
中国抗体荣获“第六届金港股”评选中“最佳中小市值公司”、“最佳CEO”奖项及“2021新浪财经金麒麟最佳港美股上市公司”评选中“最具成长潜力上市公司”奖项
中國抗體榮獲「第六屆金港股」評選中「最佳中小市值公司」、「最佳CEO」獎項及「2021新浪財經金麒麟最佳港美股上市公司」評選中「最具成長潛力上市公司」獎項
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies"
Tuesday, November 30, 2021
中国抗体公布旗舰产品SM03完成在中国III期临床试验招募
中國抗體公佈旗艦產品SM03完成在中國III期臨床試驗招募
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
Friday, November 26, 2021
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
Thursday, November 25, 2021
中国抗体受邀出席首届亚洲医疗健康高峰论坛
中國抗體受邀出席首屆亞洲醫療健康高峰論壇
Thursday, November 18, 2021
重磅!B细胞CD22单抗SM03治疗类风湿关节炎临床研究结果最新公布!

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575